Hoth Therapeutics updates pipeline timelines, reports cash runway and share count in corporate deck

Hoth Therapeutics, Inc.

Cash on hand sufficient to fund all clinical and preclinical programs in development.
13.2 million shares outstanding as of June 6, 2025; no outstanding debt noted.
HT-001 Phase 2a open-label PK data expected Q1 2025; full dataset Q4 2025.
HT-KIT IND submission targeted Q1 2026; GLP tox & GMP API manufacturing initiated Q1 2025.
HT-ALZ pre-IND meeting submission planned for 2025; 505(b)(2) pathway pursued.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.